Biocryst Pharmaceuticals, Inc.
A biopharmaceutical company that develops medicines for rare diseases, BioCryst's flagship product is Orladeyo, an oral once-daily pill that prevents attacks of hereditary angioedema, a rare genetic condition causing sudden, painful swelling. Founded in 1986 in Birmingham, Alabama, the name blends "bio" with "cryst," a nod to the X-ray crystallography technique its scientists use to design drugs at the molecular level. The company also markets RAPIVAB, an antiviral treatment for influenza.
Bought 792.8K · Sold 4.05M
Bought 342.0K · Sold 516.9K
Bought 842.5K · Sold 616.2K
Granted 2.69M · Bought 208.6K · Sold 832.7K
Bought 1.14M
Bought 108.2K · Sold 236.5K
Granted 819.2K · Bought 30.0K · Sold 6.1K
Granted 1.01M · Bought 25.0K · Sold 648.0K
Granted 263.7K · Bought 125.6K · Sold 5.7K
Granted 401.9K · Bought 30.0K · Sold 17.7K
Granted 566.6K · Bought 25.0K · Sold 274.0K
Granted 268.7K
Granted 205.2K
Granted 54.9K · Sold 50.0K
Granted 459.0K · Sold 255.6K
Bought 9.3K · Sold 15.9K
Granted 173.7K · Sold 54.3K
Granted 76.0K · Bought 22.5K
Granted 80.2K · Bought 20.0K
Granted 216.4K · Bought 25.0K · Sold 148.2K
Granted 64.2K · Bought 21.9K
Granted 202.3K · Bought 5.0K · Sold 126.6K
Granted 71.7K · Bought 7.9K
Granted 64.6K · Bought 41.6K · Sold 69.2K
Granted 50.2K · Bought 22.5K
Granted 82.5K · Bought 5.0K · Sold 18.7K
Bought 475 · Sold 37.7K
Bought 60.0K
Granted 8.3K · Bought 40.0K
Granted 67.0K · Sold 19.8K
Granted 125.3K · Bought 6.0K · Sold 100.0K
Granted 64.2K · Sold 18.3K
Bought 45.0K
Granted 825.5K · Bought 3.0K · Sold 788.0K
Granted 143.1K · Bought 6.0K · Sold 112.7K
Granted 35.5K
Granted 31.9K
Granted 100.6K · Sold 80.0K
Bought 2.3K · Sold 10.1K
Granted 27.1K · Sold 11.3K
Granted 6.0K · Bought 7.0K
Granted 12.5K
Bought 3.7K
Granted 22.6K · Bought 3.0K · Sold 22.6K
Granted 20.0K · Sold 20.0K
Granted 1.5K · Bought 1.9K · Sold 1.5K
Bought 3.0K
Granted 5.6K · Bought 508 · Sold 5.6K
Granted 60.0K · Sold 60.2K
Granted 8.1K · Sold 9.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +3 co-filers10% owner · 21 transactions | — | 38.50Mas of Aug 2016 | — | 792.8K | 4.05M |
| Baker Felix +2 co-filers10% owner · 10 transactions | — | 3.84Mas of Jun 2011 | — | 342.0K | 516.9K |
| Featheringill William WDirector, 10% owner · 25 transactions | — | 2.97Mas of Dec 2009 | — | 842.5K | 616.2K |
| Stonehouse Jon PDirector · 107 transactions | — | 2.84M | 2.69M | 208.6K | 832.7K |
| Baker Bros. Advisors LP +9 co-filers10% owner · 3 transactions | — | 1.70Mas of Aug 2013 | — | 1.14M | — |
| Baker Felix +2 co-filers10% owner · 9 transactions | — | 1.54Mas of Jun 2009 | — | 108.2K | 236.5K |
| Gayer Charles KPresident and CCO · 16 transactions | — | 902.6K | 819.2K | 30.0K | 6.1K |
| Spencer William M IIIDirector · 1 transaction | — | 543.1Kas of Dec 2006 | — | — | — |
| Barnes Alane PChief Legal Officer · 63 transactions | — | 463.2K | 1.01M | 25.0K | 648.0K |
| Doyle AnthonyChief Financial Officer · 12 transactions | — | 377.9Kas of Dec 2024 | 263.7K | 125.6K | 5.7K |
| Thackray Helen M.Chief R&D Officer · 15 transactions | — | 377.3Kas of Mar 2025 | 401.9K | 30.0K | 17.7K |
| Babu Yarlagadda SChief Discovery Officer · 65 transactions | — | 330.1Kas of Nov 2022 | 566.6K | 25.0K | 274.0K |
| Ghias BabarChief Financial Officer · 2 transactions | — | 268.7K | 268.7K | — | — |
| Menon SandeepChief R&D Officer · 1 transaction | — | 205.2K | 205.2K | — | — |
| Bugg Charles EChairman, Director · 25 transactions | — | 148.4Kas of Mar 2006 | 54.9K | — | 50.0K |
| Staab Thomas R IISenior Vice President and CFO · 134 transactions | — | 125.2Kas of May 2019 | 459.0K | — | 255.6K |
| Baker Felix +2 co-filers10% owner · 9 transactions | — | 120.8Kas of Jun 2009 | — | 9.3K | 15.9K |
| Cohen Fred EDirector · 15 transactions | — | 119.4Kas of Sep 2017 | 173.7K | — | 54.3K |
| Milano VincentDirector · 23 transactions | — | 108.5K | 76.0K | 22.5K | — |
| Ingram Robert AlexanderDirector · 25 transactions | — | 100.2Kas of Feb 2023 | 80.2K | 20.0K | — |
| Hutson Nancy JDirector · 37 transactions | — | 99.1Kas of Jun 2025 | 216.4K | 25.0K | 148.2K |
| Galson Steven KDirector · 6 transactions | — | 86.2K | 64.2K | 21.9K | — |
| Heggie TheresaDirector · 32 transactions | — | 80.6K | 202.3K | 5.0K | 126.6K |
| Levin Alan GDirector · 14 transactions | — | 79.6K | 71.7K | 7.9K | — |
| Bennett J ClaudeChief Operating Officer, Director · 34 transactions | — | 77.3Kas of Sep 2007 | 64.6K | 41.6K | 69.2K |
| Aselage SteveDirector · 19 transactions | — | 72.7Kas of Jun 2024 | 50.2K | 22.5K | — |
| Lee Kenneth B JrDirector · 8 transactions | — | 68.9Kas of Jun 2023 | 82.5K | 5.0K | 18.7K |
| Baker Felix +2 co-filers10% owner · 10 transactions | — | 62.4Kas of Jun 2011 | — | 475 | 37.7K |
| Jensen PederDirector · 4 transactions | — | 60.0Kas of Dec 2012 | — | 60.0K | — |
| Erck Stanley CDirector · 2 transactions | — | 48.3Kas of Nov 2018 | 8.3K | 40.0K | — |
| McKee Amy EDirector · 11 transactions | — | 47.2K | 67.0K | — | 19.8K |
| Grant StuartSR VP & CFO · 26 transactions | — | 46.1Kas of Mar 2011 | 125.3K | 6.0K | 100.0K |
| Sanders MachelleDirector · 8 transactions | — | 45.9K | 64.2K | — | 18.3K |
| Sniecinski MeganChief Business Officer · 1 transaction | — | 45.0Kas of Nov 2019 | — | 45.0K | — |
| Sheridan William PChief Medical Officer · 68 transactions | — | 38.0Kas of Mar 2022 | 825.5K | 3.0K | 788.0K |
| Abercrombie George BDirector · 23 transactions | — | 36.4Kas of Jun 2024 | 143.1K | 6.0K | 112.7K |
| Frank StevenDirector · 8 transactions | — | 35.5K | 35.5K | — | — |
| Milne Jill C.Director · 5 transactions | — | 31.9K | 31.9K | — | — |
| McCullough DavidVP · 11 transactions | — | 24.1Kas of Mar 2012 | 100.6K | — | 80.0K |
| Baker Felix +2 co-filers10% owner · 9 transactions | — | 18.1Kas of Jun 2009 | — | 2.3K | 10.1K |
| Jones Michael LExec. Director, Finance - PAO · 8 transactions | — | 16.7Kas of Dec 2022 | 27.1K | — | 11.3K |
| Sanders Charles ADirector · 5 transactions | — | 13.0Kas of Feb 2016 | 6.0K | 7.0K | — |
| Lowrey Robert SController, PAO · 3 transactions | — | 9.8Kas of Mar 2012 | 12.5K | — | — |
| Alexander W JamesSR. VP, Chief Medical Officer · 2 transactions | — | 3.7Kas of Jul 2007 | — | 3.7K | — |
| Darwin Michael APrincipal Accounting Officer · 30 transactions | — | 3.0Kas of Jul 2008 | 22.6K | 3.0K | 22.6K |
| Horovitz Zola PDirector · 4 transactions | — | 3.0Kas of Mar 2010 | 20.0K | — | 20.0K |
| Riggs Randall BSenior VP Business Development · 11 transactions | — | 1.9Kas of Jan 2007 | 1.5K | 1.9K | 1.5K |
| Seidenberg Beth CDirector · 2 transactions | — | 1.0Kas of May 2006 | — | 3.0K | — |
| Nugent Jonathan MVP Corp Communications · 7 transactions | — | 508as of Jul 2007 | 5.6K | 508 | 5.6K |
| Powell LynneSenior VP - CCO · 36 transactions | — | 0as of Jan 2019 | 60.0K | — | 60.2K |
| Mills MikePrincipal Accounting Officer · 8 transactions | — | 0as of Mar 2010 | 8.1K | — | 9.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -5.21M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.